查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677232

胆道癌市场按癌症类型、治疗类型、最终用户和分销管道划分 - 2025 年至 2030 年全球预测

Biliary Tract Cancers Market by Cancer Type, Treatment Type, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

胆道癌市场预计在 2024 年达到 35.8 亿美元，2025 年达到 38.6 亿美元，到 2030 年将达到 57.1 亿美元，复合年增长率为 8.09%。

主要市场统计数据
基准年 2024 年 35.8亿美元
预计 2025 年 38.6亿美元
预测年份 2030 57.1亿美元
复合年增长率（%） 8.09％

胆道癌是肿瘤学中一个复杂且具有挑战性的领域，早期诊断、快速的疾病进展和有限的治疗选择在历史上导致了高死亡率。近年来，研究重点的增加和创新的诊断和治疗策略使这一重要市场重新受到关注。这些癌症的发生率不断上升，加上分子生物学研究的进步和对其发病机制的深入了解，促使人们对临床和市场实践进行全面的重新评估。

这种动态情势凸显了整合不断发展的治疗模式和临床见解的重要性。随着相关人员不断探索新的干预措施和以患者为中心的治疗方法，整个市场正在见证学术研究、临床试验和创新技术进步的融合。本执行摘要旨在概述当前的市场动态，强调变革趋势，并为塑造胆道癌治疗未来的决策者提供重要的策略见解。

改变胆道癌症市场

近年来，胆道癌的管理和理解发生了重大的模式转移。最显着的变化之一是尖端分子诊断与个人化医疗的融合。精准医疗的重点正在改变治疗策略，将传统的一刀切模式转变为更个人化的治疗途径。同时，影像和生物标记识别技术的进步正在提高早期检测率并指南治疗决策。

此外，世界各地的监管机构都认识到这一治疗领域尚未满足的需求，并正在寻求加快有前景的治疗方法的临床途径。合作研究计划和官民合作关係关係对于推动创新也至关重要。这些转变因素与支持新的系统治疗组合的不断累积的临床证据一致。随着越来越多的临床试验采用此类创新方法，治疗方案将进一步发展，为患者带来希望，并为肿瘤领域的相关人员获得有利结果铺平道路。

这些趋势的融合代表着一个关键的转变，即对患者概况和治疗反应的更深入了解将推动临床结果的改善。这种转变迫使产业相关人员重新思考他们的价值提案，投资先进的研究和开发，并使他们的策略与不断发展的医疗保健标准保持一致。

战略细分的关键见解

深入研究市场区隔可以发现一些关键见解，这些见解将重塑人们对胆道癌的理解和管理方式。根据癌症类型分析市场可以透过区分胆管癌和胆囊癌提供详细的见解。治疗方案的动态格局进一步细分为多种方法，包括化疗、免疫疗法、放射线治疗、手术和标靶治疗，这些方法共同推动多方面的治疗生态系统。

此外，透过检视包括学术机构、癌症研究机构、医院和诊所在内的最终用户的市场，可以发现各种相关人员的优先事项如何引导市场创新和治疗策略。这些服务供应商所扮演的不断变化的角色对于将实验室发现转化为临床现实至关重要。最后，基于线下和线上平台分销管道的市场分析突显出数位转型和简化治疗方法和资讯获取方式日益增长的趋势。

这些细分洞察整合了癌症类型、治疗方式、最终用户类别和分销管道，提供了一个全面的框架来了解该领域当前的市场动态和未来的成长机会。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 提高患者和医疗保健提供者对胆道癌的认识和教育
      • 增加创新治疗解决方案研发的投资和资金
      • 全球人口老化和生活方式的改变将增加胆道癌的发生率
    • 限制因素
      • 医疗费用上涨，包括药品和外科手术费用
    • 机会
      • 影像技术创新提高胆道癌诊断准确率
      • 扩大胆道癌症标靶治疗的应用，实现患者照护
    • 任务
      • 多种症状和疾病进展使胆道癌症的诊断和治疗变得复杂
  • 市场区隔分析
    • 癌症类型：老年人胆囊癌发生率增加
    • 最终用户：癌症研究机构越来越关注识别胆道癌的潜在生物标记。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境

第六章 胆道癌市场（以癌症类型）

  • 胆管癌
  • 胆囊癌

第 7 章 胆道癌市场依治疗类型

  • 化疗
  • 免疫疗法
  • 放射治疗
  • 外科手术
  • 标靶治疗

第 8 章 胆道癌市场（依最终用户）

  • 学术机构
  • 癌症研究所
  • 医院和诊所

第九章胆道癌市场依通路划分

  • 离线
  • 在线的

第 10 章美洲胆道癌市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区胆道癌市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲胆道癌市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Delcath Systems, Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • Incyte Corporation
  • LES LABORATOIRES SERVIER
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • TAIHO PHARMACEUTICAL CO., LTD.
  • TransThera Sciences（Nanjing）, Inc.
  • Zymeworks Inc.
Product Code: MRR-094390F3C604

The Biliary Tract Cancers Market was valued at USD 3.58 billion in 2024 and is projected to grow to USD 3.86 billion in 2025, with a CAGR of 8.09%, reaching USD 5.71 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.58 billion
Estimated Year [2025] USD 3.86 billion
Forecast Year [2030] USD 5.71 billion
CAGR (%) 8.09%

Biliary tract cancers represent a complex and challenging area within oncology, where early diagnosis, rapid disease progression, and limited treatment options have historically contributed to higher mortality rates. In recent years, heightened research emphasis and innovations in diagnostic and therapeutic strategies have brought this critical market under renewed attention. The increasing prevalence of these cancers, coupled with advances in molecular research and a better understanding of disease pathology, has prompted a comprehensive reevaluation of clinical and market practices.

This dynamic landscape underscores the importance of integrating clinical insights with evolving treatment paradigms. As stakeholders continue to explore novel interventions and patient-centric care approaches, the overall market is witnessing a convergence of academic research, clinical trials, and transformative technological advancements. This executive summary is designed to provide an overview of the current market dynamics, highlight transformative trends, and offer strategic insights that are crucial for decision-makers engaged in shaping the future of biliary tract cancer care.

Transformative Shifts in the Oncology Landscape

Recent years have marked significant paradigm shifts in the management and understanding of biliary tract cancers. One of the most notable changes is the integration of cutting-edge molecular diagnostics and personalized therapies. The emphasis on precision medicine is transforming treatment strategies, shifting the traditional one-size-fits-all model towards more individualized care pathways. Concurrently, technological advancements in imaging and biomarker identification are improving early detection rates and guiding treatment decisions.

Additionally, regulatory bodies worldwide are recognizing the unmet need in this therapeutic area and are facilitating accelerated clinical pathways for promising therapies. Collaborative research initiatives and public-private partnerships have also become central to driving innovation. These transformative elements are aligned with a growing body of clinical evidence that supports novel combinations of systemic treatments. As an increasing number of clinical trials adopt these innovative methodologies, treatment protocols are expected to evolve further, offering expanded hope for patients and opening lucrative avenues for stakeholders in the oncology sector.

The convergence of these trends signifies a pivotal shift, where enhanced clinical outcomes are generating a deeper understanding of patient profiles and treatment responses. This shift is compelling industry participants to reassess their value propositions, invest in advanced R&D, and align their strategies with the evolving standards of care.

Key Insights Through Strategic Segmentation

A deep dive into market segmentation reveals vital insights that are reshaping how biliary tract cancers are understood and managed. Analyzing the market based on cancer type provides a detailed view by differentiating between Cholangiocarcinoma and Gallbladder Cancer, each presenting distinct clinical challenges and therapeutic responses. The dynamic landscape of treatment options further subdivides into multiple approaches including Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy, which collectively drive a multifaceted treatment ecosystem.

Furthermore, by examining the market through the lens of end-users, including academic institutions, cancer research institutes, and hospitals and clinics, it becomes evident that diverse stakeholder priorities are steering market innovations and treatment strategies. The evolving role of these service providers is crucial in translating laboratory discoveries into clinical realities. Lastly, analyzing the market based on the distribution channel, which spans across both offline and online platforms, highlights a growing trend towards digital transformation and streamlined access to therapies and information.

These segmentation insights, which integrate cancer types, treatment modalities, end-user categories, and distribution channels, offer a comprehensive framework for understanding both current market dynamics and future growth opportunities in the field.

Based on Cancer Type, market is studied across Cholangiocarcinoma and Gallbladder Cancer.

Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.

Based on End-User, market is studied across Academic Institutions, Cancer Research Institutes, and Hospitals & Clinics.

Based on Distribution Channel, market is studied across Offline and Online.

Regional Dynamics in the Oncology Market

The global landscape for biliary tract cancers is characterized by regional disparities and unique growth trajectories. A thorough analysis of the market reveals significant insights when viewed across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. Each regional market presents distinct epidemiological profiles, regulatory environments, and adoption rates for novel therapeutic interventions.

In the Americas, robust healthcare infrastructure combined with ongoing clinical research initiatives creates a favorable environment for rapid adoption of newly approved treatments. Moving to the Europe, Middle East & Africa region, a blend of advanced healthcare systems and emerging markets fosters a dynamic setting that balances tradition with innovation. The Asia-Pacific, meanwhile, demonstrates a rapid rise in both investment and research in oncology, driven by increasing patient awareness and significant governmental support.

Understanding these regional differences is essential for stakeholders aiming to tailor their strategies according to localized needs and regulatory requirements, thereby ensuring a more targeted and effective market penetration strategy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Benchmarking Key Market Players

The competitive landscape in the biliary tract cancer market is defined by an array of influential companies that continue to drive innovation and shape therapeutic trends. Leading the market are global players such as Agios Pharmaceuticals, Inc. and Amgen Inc., who have been at the forefront of breakthroughs in targeted therapies and novel clinical trial designs. Significant contributions are also seen from established pharmaceutical giants including AstraZeneca PLC, Basilea Pharmaceutica AG, and BeiGene, Ltd., each leveraging their expansive R&D capabilities to refine and expand treatment options.

Small and mid-sized biotech firms like Bristol-Myers Squibb Company and Delcath Systems, Inc. have also played pivotal roles by introducing innovative diagnostic techniques and therapeutic interventions. Moreover, companies such as Eisai Co., Ltd., Eli Lilly and Company, and Exelixis, Inc. are known for their commitment to precision medicine and advanced clinical research. Industry leaders including F. Hoffmann-La Roche Ltd, Incyte Corporation, LES LABORATOIRES SERVIER, and Merck & Co., Inc. are driving strategic investments that have spurred countless advancements. The competitive arena is further intensified by key players such as Novartis AG, Pfizer Inc., Sanofi S.A., TAIHO PHARMACEUTICAL CO., LTD., TransThera Sciences (Nanjing), Inc., and Zymeworks Inc., who continue to expand their portfolios in a bid to address both current and emerging treatment challenges.

Such a diverse group of market participants underscores the highly competitive nature of the sector and the collective drive toward enhancing patient outcomes through innovative solutions.

The report delves into recent significant developments in the Biliary Tract Cancers Market, highlighting leading vendors and their innovative profiles. These include Agios Pharmaceuticals, Inc., Amgen Inc., AstraZeneca PLC, Basilea Pharmaceutica AG, BeiGene, Ltd., Bristol-Myers Squibb Company, Delcath Systems, Inc., Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd, Incyte Corporation, LES LABORATOIRES SERVIER, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., TAIHO PHARMACEUTICAL CO., LTD., TransThera Sciences (Nanjing), Inc., and Zymeworks Inc.. Strategic Recommendations for Future Growth

Leaders looking to capitalize on opportunities within the biliary tract cancers segment should focus on a multifaceted approach to growth that addresses both immediate clinical needs and long-term market sustainability. Increasing investments in research and development must be paired with collaborative initiatives that bridge the gap between scientific discovery and clinical application. Partnerships with academic institutions and research networks can be highly beneficial in accelerating innovative breakthroughs, while also enhancing the overall credibility and reach of new treatment modalities.

In parallel, market leaders should broaden their strategic focus by harnessing digital transformation-leveraging online distribution channels and telemedicine to expand access to care and streamline patient engagement. Emphasizing real-world evidence through robust data collection and analysis can further refine treatment protocols and foster a continuous cycle of improvement. Additionally, diversifying treatment portfolios by incorporating advanced immunotherapy and targeted therapy solutions is critical in meeting the varied needs of patient demographics.

A proactive approach that combines comprehensive market intelligence, adaptive regulatory strategies, and robust commercialization plans is key to seizing the growing opportunities in this sector. This balanced strategy not only aims to enhance clinical outcomes but also optimizes operational efficiency and strengthens competitive positioning in an increasingly dynamic environment.

Conclusion and Future Outlook

The evolving market for biliary tract cancers is marked by rapid innovations and disruptive trends that are reshaping the treatment paradigm. With a solid foundation built on advanced molecular research, diversified treatment options, and robust market segmentation, the outlook for this sector remains promising. The interplay of clinical advancements and strategic market insights is transforming how stakeholders approach challenges in early diagnosis, treatment efficiency, and patient management.

Continued investments in R&D, coupled with strategic alliances and modernized distribution models, are set to drive sustained market growth. In the face of rising patient expectations and evolving regulatory landscapes, the focus on personalized care and data-driven decision-making remains more crucial than ever. Ultimately, this dynamic shift paves the way for further enhancements in clinical outcomes while offering new channels for innovation and competitive differentiation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising awareness and education about biliary tract cancers among patients and healthcare providers
      • 5.1.1.2. Growing investments and funding in research and development for innovative treatment solutions
      • 5.1.1.3. Increasing incidence of biliary tract cancers driven by aging population and lifestyle changes globally
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment including pharmaceuticals and surgical interventions
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in imaging technology for enhanced accuracy in biliary tract cancer diagnosis
      • 5.1.3.2. Expanding use of targeted therapies in biliary tract cancers for personalized patient care
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of diagnosing and managing biliary tract cancers due to varied symptoms and disease progression
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cancer Type: Increasing prevalence of gallbladder cancer in older populations
    • 5.2.2. End-User: Growing focus of cancer research institutes on identifying potential biomarkers for biliary tract cancers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biliary Tract Cancers Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Cholangiocarcinoma
  • 6.3. Gallbladder Cancer

7. Biliary Tract Cancers Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy
  • 7.4. Radiation Therapy
  • 7.5. Surgery
  • 7.6. Targeted Therapy

8. Biliary Tract Cancers Market, by End-User

  • 8.1. Introduction
  • 8.2. Academic Institutions
  • 8.3. Cancer Research Institutes
  • 8.4. Hospitals & Clinics

9. Biliary Tract Cancers Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Americas Biliary Tract Cancers Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biliary Tract Cancers Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biliary Tract Cancers Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Groundbreaking FDA approval of Roche's HER2 companion diagnostic boosts treatment for advanced biliary tract cancer
    • 13.3.2. Zymeworks achieves regulatory milestones with zanidatamab in HER2-positive biliary tract cancer treatment advancements
    • 13.3.3. Breakthrough global phase 3 trial of tinengotinib receives EU authorization and orphan drug status for biliary tract cancer treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agios Pharmaceuticals, Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Basilea Pharmaceutica AG
  • 5. BeiGene, Ltd.
  • 6. Bristol-Myers Squibb Company
  • 7. Delcath Systems, Inc.
  • 8. Eisai Co., Ltd.
  • 9. Eli Lilly and Company
  • 10. Exelixis, Inc.
  • 11. F. Hoffmann-La Roche Ltd
  • 12. Incyte Corporation
  • 13. LES LABORATOIRES SERVIER
  • 14. Merck & Co., Inc.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.
  • 18. TAIHO PHARMACEUTICAL CO., LTD.
  • 19. TransThera Sciences (Nanjing), Inc.
  • 20. Zymeworks Inc.

LIST OF FIGURES

  • FIGURE 1. BILIARY TRACT CANCERS MARKET MULTI-CURRENCY
  • FIGURE 2. BILIARY TRACT CANCERS MARKET MULTI-LANGUAGE
  • FIGURE 3. BILIARY TRACT CANCERS MARKET RESEARCH PROCESS
  • FIGURE 4. BILIARY TRACT CANCERS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BILIARY TRACT CANCERS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES BILIARY TRACT CANCERS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. BILIARY TRACT CANCERS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. BILIARY TRACT CANCERS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BILIARY TRACT CANCERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BILIARY TRACT CANCERS MARKET DYNAMICS
  • TABLE 7. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY GALLBLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BILIARY TRACT CANCERS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES BILIARY TRACT CANCERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BILIARY TRACT CANCERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BILIARY TRACT CANCERS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM BILIARY TRACT CANCERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM BILIARY TRACT CANCERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. BILIARY TRACT CANCERS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 192. BILIARY TRACT CANCERS MARKET, FPNV POSITIONING MATRIX, 2024